Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Conditions: Pulmonary Tuberculosis Interventions: Drug: GSK3036656; Drug: BTZ-043; Drug: Bedaquiline (B); Drug: Delamanid (D); Drug: Pretomanid (Pa); Drug: Moxifloxacin (M); Drug: Linezolid (L); Drug: Pyrazinamide (Z); Drug: Rifampicin (R); Drug: Isoniazid (H); Drug: Ethambutol (E) Sponsors: University College, London; Radboud University Medical Center; London School of Hygiene and Tropical Medicine; University of Oxford; Research Center Borstel; Lygature; TASK Applied Science; Vita-Salute San Raffaele University; Helmholtz Zentrum Munchen; KNCV Tuberculosis Foundation; Critical Path Institute; European Lung Foundation; Instituto de Saude Publica da Universidade do Porto; University of Liverpool; Institut de Recherche Pour le Developpment; University of Hamburg-Eppendorf; University of California, San Francisco; TB Alliance; Find; University of Milano; University of St Andrews; Uppsala University; European Respiratory Society; Tuberculosis Network European Trialsgroup; Janssen, LP; Otsuka Pharmaceutical Development& Commercialization, Inc.; German Center for Infection Research; LMU University Hospital Munich; University of Cambridge; GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials